Dept of Pathology, Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA.
Am J Clin Pathol. 2010 Dec;134(6):964-9. doi: 10.1309/AJCPH92SXYLIKKTS.
Changes in quantitative D-dimer levels, circulating tumor cell (CTC) counts, and prostate-specific antigen (PSA) levels were measured in 28 patients with refractory castration-resistant prostate cancer to assess their concordance during the course of therapy and their relationship with risk of progressive disease. A significant correlation was identified between changes in PSA and both CTC counts and D-dimer levels (r = 0.67 and 0.58, respectively; P < .001). In addition, there was a significant correlation between changes in CTC count and D-dimer level (r = 0.62; P < .001). A significantly stronger concordance between these biomarkers was noted for increasing values (sensitivity, 72%-77.8%) compared with decreasing values (specificity, 43.8%-71.4%). Notably, increases in PSA and D-dimer levels, not CTC counts, were associated with increased risks for progressive disease (P < .024). Increases in quantitative D-dimer levels correlate with progressive disease better than CTC counts in patients with refractory prostate cancer.
在 28 例难治性去势抵抗性前列腺癌患者中测量了定量 D-二聚体水平、循环肿瘤细胞 (CTC) 计数和前列腺特异性抗原 (PSA) 水平的变化，以评估它们在治疗过程中的一致性及其与疾病进展风险的关系。PSA 变化与 CTC 计数和 D-二聚体水平之间均存在显著相关性 (r = 0.67 和 0.58，均 P <.001)。此外，CTC 计数与 D-二聚体水平之间也存在显著相关性 (r = 0.62；P <.001)。与下降值相比 (敏感性，43.8%-71.4%)，这些生物标志物的上升值之间具有更强的一致性 (特异性，72%-77.8%)。值得注意的是，PSA 和 D-二聚体水平的升高，而不是 CTC 计数，与疾病进展风险增加相关 (P <.024)。在难治性前列腺癌患者中，定量 D-二聚体水平的升高比 CTC 计数更能与疾病进展相关。
